|
|
||||||||
1From the Department of Ophthalmology and Visual Sciences, Kentucky Lions Eye Center, University of Louisville, Louisville, Kentucky.
PURPOSE. The aims of this study were to determine whether IL-17+ T cells were present in CD4 and CD8 interphotoreceptor retinoid-binding protein (IRBP)-specific T cells and to determine the role of antigen-specific and nonspecific IL-17+ T cells in the pathogenesis of experimental autoimmune uveitis (EAU).
Methods.
B6 mice were immunized with uveitogenic peptide IRBP1–20. In vivo-primed T cells were separated and stimulated with the immunizing peptide. Intracellular expression of IFN-
and IL-17 by the T cells was assessed, and the pathogenic activity of the activated T cells was determined.
Results.
A subset of autoreactive IRBP-specific CD8 T cells expressed IL-17. IRBP-specific T cells preferentially expressed IL-17 when expanded by IL-23, whereas IFN-
–expressing cells were dominant when the T cells were cultured with IL-2. Importantly, both expanded T-cell populations were uveitogenic. In addition, IL-23 promoted the expansion of antigen-specific and non–antigen-specific IL-17+ T cells, whereas TGF-ß and IL-6 acted only on non–antigen-specific IL-17+ T cells. Only the antigen-specific IL-17+ T cells were uveitogenic. The activation of autoreactive IL-17+ T cells was markedly increased in vivo by the mycobacterial component of CFA and pertussis toxin (PTX) and in vitro by the ligation of Toll-like receptors.
Conclusions.
IL-17+ T cells can be readily detected among activated autoreactive and bystander T cells and may play a major role in the pathogenesis of EAU.
This article has been cited by other articles:
![]() |
R. K. Agarwal, R. Horai, A. M. Viley, P. B. Silver, R. S. Grajewski, S. Bo Su, A. T. Yazdani, W. Zhu, M. Kronenberg, P. J. Murray, et al. Abrogation of Anti-Retinal Autoimmunity in IL-10 Transgenic Mice Due to Reduced T Cell Priming and Inhibition of Disease Effector Mechanisms J. Immunol., April 15, 2008; 180(8): 5423 - 5429. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |